Home World News Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients... World News Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC By Ogkologos - September 3, 2026 118 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5-year follow-up analysis of the KEYNOTE-564 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Καρκίνος οισοφάγου January 22, 2019 EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate October 29, 2026 ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 EMA Recommends Granting a Marketing Authorisation for Lurbinectedin April 30, 2026 Load more HOT NEWS How I Learned to Advocate for Myself During Cancer: “Your Stories”... Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer New on NCI’s Websites for June 2020 Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with...
